Description
ARA-290 is a synthetic peptide derived from a non-hematopoietic region of erythropoietin (EPO) that is studied for its interaction with tissue-protective receptor signaling. ARA-290 peptide research focuses on how this short peptide engages the EPOR–CD131 receptor complex (often described as an innate repair receptor) and how that signaling influences cellular responses under controlled experimental conditions. Unlike full-length EPO, ARA-290 is investigated for pathway-selective activity in models that do not center on erythropoiesis.
In vitro experiments and animal studies commonly evaluate changes in inflammatory cytokine profiles, endothelial and immune cell activation markers, and tissue remodeling indicators. Major research areas include immune signaling modulation, vascular biology endpoints (such as endothelial progenitor behavior), and preclinical models of peripheral nerve structure and function. These systems matter in laboratory research because they provide quantifiable markers of inflammation, cellular survival pathways, and repair-associated signaling without implying clinical outcomes or human use.
For research use only. Not for human consumption.
References:
Brines M et al., Proc Natl Acad Sci USA, 2008 105(31):10925–10930
Ehrenreich H et al., Mol Med, 2010 16(9-10): 440–446
Ostrowski D et al PLoS One, 2017 12(10): e0185838
Reviews
There are no reviews yet.